BBIO Q4 2020 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$122,000-99.1% YoY

Gross Profit

$122,000100.0% margin

Operating Income

-$127M-104499.2% margin

Net Income

-$120M-98345.1% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

-98.5%

Cash Flow

Operating Cash Flow

-$96M

Free Cash Flow

-$98M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$704M

Total Liabilities

$596M

Stockholders' Equity

$58M

Cash & Equivalents

$356M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$122,000	$14M	-99.1%
Gross Profit	$122,000	$14M	-99.1%
Operating Income	-$127M	-$79M	-62.1%
Net Income	-$120M	-$73M	-63.3%